PeptideWiki

AMA urges HHS to rescind its peptide compounding policy as the comment period closes

Published by the PeptideWiki editorial team.

BPC-157 TB-500 KPV MOTS-c Semax Epitalon

On November 9 the AMA adopted policy urging HHS and FDA to rescind steps that ease compounding of unapproved peptides. Comments on HHS's six-peptide policy close November 13.

On November 9, 2026, the American Medical Association adopted policy urging HHS and FDA to "immediately rescind" peptide compounding policies. Its target is any step that eases restrictions on compounding unapproved synthetic peptides. The vote came at the AMA's Interim Meeting in Orlando. It follows, by less than two weeks, an HHS policy saying it will not take enforcement action against pharmacies compounding six peptides. Public comments on that HHS policy close today, November 13.

Research material: BPC-157 at Fifth Ave Labs · BPC-157 at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.

Research material: TB-500 at Fifth Ave Labs · TB-500 at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.

Research material: KPV at Fifth Ave Labs · KPV at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.

Research material: MOTS-c at Fifth Ave Labs · MOTS-c at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.

Research material: Semax at Fifth Ave Labs · Semax at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.

Research material: Epitalon at Fifth Ave Labs · Epitalon at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.

What the AMA adopted

The AMA's House of Delegates sets the association's policy. The new policy says unapproved synthetic peptides "lack the safety, efficacy, and quality evidence necessary to support their use."

According to the AMA's release, the policy commits the association to two things:

  • Urging HHS, FDA and other federal regulators to immediately rescind administrative policies or directives that ease restrictions on compounding and distributing synthetic peptides that lack FDA approval.
  • Working with federal agencies, state medical boards and state pharmacy boards on enforcement. The named targets are compounding pharmacies, direct-to-consumer telehealth platforms and online dispensaries distributing unapproved peptides.

AMA board member Ilse R. Levin, DO, spoke to the risk. She said that compounding without enough safety and efficacy evidence puts patients "at increased risk of serious harm."

The release does not name the HHS policy. Becker's Hospital Review pointed out that omission, and the timing of the vote.

The HHS peptide compounding policy it responds to

On October 28, HHS announced an interim enforcement discretion policy for 503A compounding with six peptide bulk substances: BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. Our earlier post covers what it does and does not do.

Holland & Knight's summary lists 10 conditions that must all be met. They include sourcing from an FDA-registered, CGMP-compliant original manufacturer and a valid certificate of analysis. That certificate must cover identity, purity, potency and contaminants such as endotoxins, heavy metals and microbes. Products must contain a single active ingredient, and serious adverse events go to FDA's MedWatch program.

The policy does not add any peptide to the 503A bulks list. It is not binding on HHS or the public, and HHS says it may revisit it. It also does not extend to research-use-only material. For the difference between pharmacy types, see 503A vs 503B compounding.

Date (2026)BodyActionLegal effect
JulyFDA Pharmacy Compounding Advisory CommitteeRecommended six of seven reviewed peptides for the 503A bulks listAdvisory only
October 28HHS Office of the SecretaryInterim enforcement discretion policy for the six peptidesNot binding; can be revisited
November 9AMA House of DelegatesPolicy urging rescission and stronger enforcementNo legal force
November 13HHS, docket HHS-OASH-2026-0496Public comment period closesHHS may keep, revise or withdraw the policy

Why state boards matter

An AMA policy has no legal force, as Medical Daily noted. Its leverage runs through the bodies it plans to work with.

Traditional 503A pharmacies are regulated mainly by state boards of pharmacy and state health departments. Holland & Knight notes the HHS policy covers only federal enforcement. It does not stop states from restricting, prohibiting or conditioning the compounding of these peptides.

That means the next real changes could come state by state, even if HHS keeps its federal policy unchanged. The AMA's plan to engage state medical and pharmacy boards points in that direction.

The evidence question behind the dispute

The disagreement is about evidence. FDA's Center for Drug Evaluation and Research had recommended against listing the six peptides, per Holland & Knight. HHS instead relied on the advisory committee vote, documented historical use, lot-specific characterization data and the policy's safeguards.

Medical Daily reported that FDA briefing materials found the available studies short, small and insufficient to establish safety or effectiveness. That included five studies of BPC-157. Citing AJMC, it reported the committee vote on BPC-157, KPV and TB-500 as 8 to 6 with one abstention.

Medical Daily also cited AJMC on FDA adverse event reports. It reported 10 serious reports tied to BPC-157 since 2021, eight of them in 2026. Such reports do not show that the peptide caused the events.

Human evidence for all six peptides remains limited. FDA reviewers found little human data, Medical Daily reported. Our guide to reading preclinical research explains why those results do not transfer directly to people.

What to watch next

  • HHS's response to comments. After the docket closes, HHS can keep, revise or withdraw the interim policy.
  • FDA rulemaking. Holland & Knight calls the formal 503A bulks list rulemaking the more consequential long-term step. It will decide whether these peptides become formally eligible for compounding.
  • State action. Watch state pharmacy and medical boards, which the AMA now plans to engage.
  • Quality documentation. The policy's conditions lean on certificates of analysis and contaminant testing. Our guides to reading a COA and endotoxin testing cover what those documents should show.

We log each dated step, with sources, in the regulatory tracker.

Research material: BPC-157 at Fifth Ave Labs · BPC-157 at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.

Research material: TB-500 at Fifth Ave Labs · TB-500 at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.

Research material: KPV at Fifth Ave Labs · KPV at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.

Research material: MOTS-c at Fifth Ave Labs · MOTS-c at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.

Research material: Semax at Fifth Ave Labs · Semax at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.

Research material: Epitalon at Fifth Ave Labs · Epitalon at Legion Peptides. For qualified researchers only. Lot-specific COA on each product page. For laboratory research use only. Not for human or veterinary use.

Sources

  1. American Medical Association: AMA adopts new policies to protect patients and strengthen public health (Nov 9, 2026)
  2. Holland & Knight: HHS Issues Interim Enforcement Discretion Policy for Compounding of 6 Peptides (Nov 4, 2026)
  3. Becker's Hospital Review: New AMA policy targets unapproved peptide compounding (Nov 10, 2026)
  4. Medical Daily: AMA Urges HHS to Rescind Policies Easing Compounding of Unapproved Peptides (Nov 12, 2026)

Educational content only, not medical advice. Compounds discussed as research materials are for laboratory research use only and are not for human or veterinary use.

More from the blog